SPRAVATO™, or Esketamine, is an innovative FDA-approved treatment that has relieved thousands of individuals suffering from treatment-resistant depression. Administered as a nasal spray under the supervision of a certified healthcare provider, SPRAVATO™ is unique in that it may be able to alleviate symptoms of depression within hours rather than the weeks or months a typical antidepressant may take. While a standard antidepressant, such as the SSRIs Fluoxetine (Prozac) or Sertraline (Zoloft), targets specific neurotransmitters in the brain like serotonin, SPRAVATO™ targets the NMDA receptor within nerve cells and helps reset these connections between nerve cells. SPRAVATO™ went through both short-term and long-term trials before the FDA approved it for use with treatment-resistant depression.
How Is SPRAVATO™ Different?
Rising depression rates worldwide make one thing clear: the current antidepressants so commonly prescribed are not bringing adequate relief to all those suffering. These oral antidepressants typically aim to treat depression by increasing certain neurotransmitters in the brain to affect mood. SPRAVATO™ works differently – it targets the NMDA receptor antagonist and may be able to reset and restore neuronal connections. Through this, SPRAVATO™ can treat the disorder, not just the symptoms.
Now There Can Be Relief for Treatment-Resistant Depression
Depression is not as simple as just “sadness.” Sadness is a feeling that comes and goes with everyday life. Almost 300 million people suffer from depression worldwide, and despite a variety of depression treatments available, many continue to suffer without relief from these medications.
Fortunately, SPRAVATO™ – the breakthrough FDA-approved esketamine nasal spray – is showing excellent results in relieving those symptoms of depression. As a SPRAVATO™ REMS-certified treatment provider, our treatment team can alleviate even the most severe forms of treatment-resistant depression.
